Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Amniotic Membrane Extract Eye Drop
- Development stage
- Unknown
- Lead developer
- Royan Institute
- Administration
- Ophthalmic, Topical
01
Overview
Amniotic Membrane Extract Eye Drop (AMEED) is a biologic therapy developed by the Royan Institute for Stem Cell Biology and Technology. It is a cocktail of soluble bioactive factors derived from human amniotic membrane (HAM), produced by homogenizing the tissue and collecting the supernatant. The extract contains several growth factors and bioactive molecules, including epidermal growth factor (EGF), keratinocyte growth factor (KGF), hepatocyte growth factor (HGF), and interleukin-1 receptor antagonist (IL1RA). AMEED is administered topically as eye drops and is designed to promote the proliferation of limbal stem cells and accelerate the healing of the corneal epithelium. It is primarily being evaluated in clinical trials for the treatment of unilateral limbal stem cell deficiency (LSCD) caused by chemical burns, where it serves to support in vivo cultivation of stem cells.
- Other names
- Amniotic Membrane ExtractHuman Amniotic Membrane Extract
02
Targets
IL-1R (Interleukin-1 receptor type 1 (IL-1R1))MET (Mesenchymal-epithelial transition factor receptor)FGFR2 (Keratinocyte growth factor receptor)EGFR (Epidermal growth factor receptor)
Beyond the preview
Go deeper on Amniotic Membrane Extract Eye Drop.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Amniotic Membrane Extract Eye Drop.